Treats hypertension. ANDA 210847, held by PharmoBedient. Felodipine.
As of Nov 21, 2026, ANDA 210847 (Felodipine), held by PharmoBedient, was first approved by FDA on Oct 26, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Felodipine Extended-release Tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2018 | Original application | Approved | None posted |
| Felodipine2.5MG · tablet, extended release;oral | Felodipine | Rx |
| Felodipine5MG · tablet, extended release;oral | Felodipine | Rx |
| Felodipine10MG · tablet, extended release;oral | Felodipine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters